Abstract
Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors. Subsequent iterations of analogue design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochemical properties of lead compounds. Those analogues exhibiting improved solubility and membrane permeability were shown to have notably enhanced pharmacokinetic profiles. Additionally, a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compound BMS-791325 (2) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Allosteric Regulation
-
Animals
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / pharmacology*
-
Benzazepines / chemistry
-
Benzazepines / pharmacokinetics
-
Benzazepines / pharmacology*
-
Dogs
-
Drug Discovery
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Indoles / chemistry
-
Indoles / pharmacokinetics
-
Indoles / pharmacology*
-
Magnetic Resonance Spectroscopy
-
Mass Spectrometry
-
Models, Molecular
-
Rats
-
Structure-Activity Relationship
-
Viral Nonstructural Proteins / antagonists & inhibitors*
Substances
-
8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide
-
Antiviral Agents
-
Benzazepines
-
Enzyme Inhibitors
-
Indoles
-
Viral Nonstructural Proteins
-
NS-5 protein, hepatitis C virus